Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • nohopeN Offline
    nohopeN Offline
    nohope
    wrote on sidst redigeret af
    #135

    Spørger bare for at sige noget, skal ikke bruges til noget nyttigt.

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #136

      pil op

      1 Reply Last reply
      0
      • D Offline
        D Offline
        deleted-user
        wrote on sidst redigeret af
        #137

        ? Børsen?

        1 Reply Last reply
        0
        • A Offline
          A Offline
          AaBforever
          wrote on sidst redigeret af
          #138

          Gen­mab over­går for­vent­nin­ger i tred­je kvar­tal/Børsen

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #139

            Link Preview Image
            Siden findes ikke

            favicon

            (borsen.dk)

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #140

              Rapporten: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-nine-months-2020

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #141

                Is this one new? JNJ-70218902
                • Phase 1 study in advanced stage solid tumors ongoing
                • Developed by Janssen under the DuoBody technology collaboration
                / JNJ-70218902 is a bispecific antibody created by Janssen using Genmab's DuoBody technology. It is
                being investigated in a Phase 1 clinical study for the treatment of advanced stage solid tumors.
                Third Quarter 2020 Update
                • September: A Phase 1 study of JNJ-70218902 in patients with advanced solid tumors was
                initiated.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #142

                  it is in trial for Metastatic Castration-Resistant Prostate Cancer https://clinicaltrials.gov/ct2/show/NCT04397276

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    GeorgeBest
                    wrote on sidst redigeret af
                    #143

                    Sounds new E L

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #144

                      and PRV-015 (AMG 714)
                      • Antibody targeting IL-15
                      • In clinical development for celiac disease
                      ?

                      1 Reply Last reply
                      0
                      • A Offline
                        A Offline
                        AaBforever
                        wrote on sidst redigeret af
                        #145

                        Biotek...healthcare... ok i dag...tror også nohope er tilfreds..:-D

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #146

                          in august "Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease " https://www.prnewswire.com/news-releases/provention-bio-announces-initiation-of-phase-2b-proactive-study-of-prv-015-anti-il-15-in-non-responsive-celiac-disease-301120649.html

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #147

                            Just a moment...

                            favicon

                            (www.proinvestor.com)

                            1 Reply Last reply
                            0
                            • A Offline
                              A Offline
                              AaBforever
                              wrote on sidst redigeret af
                              #148

                              Men spændende at se hvad der sker de næste timer/
                              dage i US.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #149

                                PRV-015 in Gluten-free Diet Non-responsive Celiac Disease (PROACTIVE) https://clinicaltrials.gov/ct2/show/NCT04424927?term=PRV-015&draw=2&rank=1

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #150

                                  hmmm, the €20mn Curevac investment now worth dkk644mn...

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #151

                                    Succes hele vejen rundt 😉

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #152

                                      audio isn't great on this call, i hope you can hear it better than
                                      me...

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #153

                                        epco abstract there now - Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes https://ashpublications.org/blood/article/136/Supplement 1/45/470017/Subcutaneous-Epcoritamab-Induces-Complete?searchresult=1

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #154

                                          Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20) https://ashpublications.org/blood/article/136/Supplement 1/35/472423/Novel-Semi-Mechanistic-Model-Leveraging?searchresult=1

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger